Table 2.

Univariate and multivariate analysis of progression-free survival

	Univariate analysis		Multivariate analysis
	HR (95%CI)	p value	HR (95%CI)	p value
sex	1.79(1.12–2.89)	0.02	2.71(1.14–6.42)	0.02
Age (years)	0.84(0.52–1.35)	0.47
smoking	1.61(0.99–2.59)	0.05	0.59(0.24–1.44)	0.25
T stage	0.35(0.20–0.63)	< 0.001	1.30(1.06–1.59)	0.01
N stage	0.95(0.59–1.52)	0.82
EGFR mutation	0.94(0.62–1.44)	0.78
No. mets	0.92(0.57–1.47)	0.72
No. mets. Organs	0.51(0.22–1.18)	0.12
lung mets	1.26(0.77–2.06)	0.37
bone mets	1.55(0.94–2.55)	0.08
adrenal gland mets	2.49(0.90–6.91)	0.08
brain mets	1.38(0.85–2.27)	0.19
LN mets	1.14(0.70–1.84)	0.60
Osimertinib	0.73(0.42–1.27)	0.27
LCT	0.48(0.27–0.88)	0.02	0.29(0.12–0.68)	0.004

Abbreviations: LCT local consolidative therapy, No number, mets metastasis, LN lymph node